Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

Because PAH can be severe and often challenging to treat, it can lead to severe short- and long-term health challenges. Read on to learn more about the medications available to treat PAH ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

DelveInsight’s, “Pulmonary Arterial Hypertension Pipeline Insight” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension ...